Background: Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. Methods: We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifthgeneration assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. Results: cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-to-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with
Introduction
The polycystic ovarian syndrome (PCOS) was recognized more than 80 years ago and is one of the most common causes of reproductive and metabolic dysfunction in women [1] . The prevalence of this disorder globally has been generally reported to be between 5% and 15%. The diagnosis of PCOS centers on the presence of hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology [1] . Patients with PCOS also have a number of comorbidities, including menstrual dysfunction, dysfunctional uterine bleeding and increased risk for endometrial carcinoma; insulin (INS) resistance, hyperinsulinemia, and increased risk for diabetes mellitus, hypertension, metabolic dysfunction and possibly cerebro-and cardiovascular disease; and psychosexual dysfunction [2] .
In PCOS, hyperandrogenism can be evident clinically (e.g., hirsutism) or biochemically, including the elevation of total testosterone (TT) and free testosterone (FT), and other androgenic steroids and metabolites in the circulation [3] . Biochemical evaluation currently requires remote measurement of these specimens for most patients as the methodologies used require radioactivity or expensive mass spectrometry instrumentation not available to the standard hospital laboratory. This shipping of the specimen for analysis can delay patient diagnosis confirmation for weeks, causing delays in care and increased psychological stress to patients. In men, serum prostate-specific antigen (PSA) is a well-known marker not only of prostatic carcinoma [4] but also of circulating androgens [5] . Previously, it was believed that PSA did not exist in any female tissue or fluid because it is produced in men by the prostate gland, an organ women do not have. However, our group convincingly demonstrated that PSA is produced in significant amounts by many tissues in females, including breast, periurethral, salivary and thyroid tissues, and by many tumors [6, 7] . We and others have also demonstrated that the PSA gene is upregulated by androgens and progestins in breast and other female tissues, as well as in model systems such as breast carcinoma cell lines [8] [9] [10] [11] .
In hirsute females and those with PCOS, serum and/ or urine PSA have been reported to be elevated [12] [13] [14] . Our own previous study reported urinary PSA levels almost 200-fold higher in females with PCOS in comparison with controls [12] . Vural et al [13] . reported serum PSA elevations in patients with PCOS, a finding confirmed by others [14] [15] [16] [17] [18] . We have further documented that serum and urine PSA levels are highly elevated in female-to-male transsexuals after testosterone treatment, thereby demonstrating that androgens regulate PSA synthesis in female tissues in vivo [19, 20] .
PSA circulates in blood as a complex with α 1 -antichymotrypsin (ACT) (complexed PSA [cPSA]), which accounts for approximately 80% of total PSA, as well as in free form (free PSA [fPSA] or noncomplexed PSA), which accounts for the remaining 20% of total PSA [21, 22] . Although the original PSA assays had limits of detection of around 0.1 ng/mL for total PSA, third-generation assays, developed about 20 years ago, achieve detection limits of around 1 pg/mL for total PSA [23, 24] . However, even with such levels of sensitivity, PSA assays could not accurately quantify cPSA or fPSA levels in the female circulation because the levels of these fractions in females are extremely low (around 1 pg/mL, or close to the detection limit of such assays) [25] . Recently, fifth-generation PSA assays with sensitivities in the 0.1-0.01 pg/mL range have been developed, which is enough to accurately quantify both cPSA and fPSA in the circulation of females [26] [27] [28] [29] [30] [31] .
In the present study, we hypothesize that the measurement of cPSA and fPSA may serve as an alternative to androgen (TT and FT) measures in evaluating for biochemical hyperandrogenism in the PCOS [32] .
Materials and methods

Subjects
Subject selection criteria have been reported previously [3] . Some details are described below.
Serum samples from 45 women with PCOS were studied. The presence of PCOS was defined according to the NIH 1990 criteria, including (1) clinical evidence of hyperandrogenism and/or hyperandrogenemia, (2) oligo-ovulation and (3) exclusion of related disorders (e.g., congenital adrenal hyperplasia, thyroid dysfunction and hyperprolactinemia) as previously defined [33, 34] . The degree of body and facial terminal hair growth was assessed visually by the modified Ferriman-Gallwey (mFG) score. The degree of hyperandrogenemia was assessed by the measurement of TT and FT, androstenedione (A4) and dehydroepiandrosterone sulfate (DHEAS). Ovulatory dysfunction was defined as menstrual cycles of greater than 45 days in length or less than eight cycles per year, or by a luteal phase (cycle days 22-24) progesterone level of less than 4 ng/mL (12.7 nmol/L) if cycles were less than 45 days in length.
Serum samples from 40 healthy control women were also studied. Controls were defined as healthy nonpregnant, nonhirsute, premenopausal, eumenorrheic women without personal or family history of hirsutism and/or endocrine disorders. Controls were recruited by responding to posted advertisements.
Neither PCOS nor control subjects were taking any medications that could impact hormonal levels for at least 3 months before blood collection, and all underwent a history and physical examination. A fasting blood sample was obtained during the follicular phase (cycle days 3-8) of the menstrual cycle or, if oligo-amenorrheic, at days 3-8 after a withdrawal bleed was induced with oral micronized progesterone. Serum samples were kept frozen at −80 °C until thawed for analysis. All subjects were recruited either at the University of Alabama at Birmingham (UAB) or at Cedars-Sinai Medical Center (CSMC); the study was approved by the Institutional Review Boards for Human Protection of UAB and CSMC. Written consent was obtained from all subjects. Some of these subjects were reported previously [3] .
Hormonal and chemical assays
TT and FT were measured as previously described [3, 35] . In brief, TT was measured by high-turbulence liquid chromatography tandem mass spectrometry (LC-MS/MS; Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA). In brief, TT measurement by LC-MS/MS was performed by first preanalytically processing the samples and included acidifying, addition of internal standard, autosampling and separation by a high-turbulence liquid chromatography column followed by passage through a C12 analytical high-pressure liquid chromatography column. TT was then quantitated using a Finnigan TSQ Quantum Ultra (ThermoFisher, San Jose, CA, USA) tandem mass spectrometer. The sensitivity of the assay (LOQ), set at a coefficient of variation (CV) of 20%, was 0.3 ng/dL [0.01 nmol/L]. The CV for all reproducibility data was <15% and ranged from 7.6% to 10.8% for intra-assay and 9.8% to 13.4% for inter-assay variability.
FT was determined by equilibrium dialysis (Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA), based on the TT measure, as previously described [3, 35] . In brief, serum samples were diluted in the presence of tritiated testosterone as the tracer. The diluted sample was placed on the sample side of the dialysis chamber and the same physiological salt buffer without tracer was placed on the other (buffer) side. The tracer was allowed to reach equilibrium with the endogenous testosterone and the binding proteins. Following incubation, a sample from each side of the membrane was removed, and the amount of tracer present in each was determined. The FT concentration was then calculated from the percent of tracer that crossed to the other side of the chamber and the TT concentration, as determined by the method outlined above.
Androstenedione (A4), dehydroepiandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) were measured as previously described [34] . In brief SHBG activity was measured by competitive binding, using Sephadex G-25 and [ 3 H]T as the ligand. DHEAS and A4 were measured by direct RIA using commercially available kits (S+DHEAS from Diagnostic Products Corp., Los Angeles, CA, USA; A4 from Diagnostic Systems Laboratories, Webster, TX, USA). The glucose (GLU) and INS assays were performed as previously described [36] . In brief, GLU assays were performed with Ektachem DT slides (Johnson & Johnson Clinical Diagnostics, Rochester, NY, USA), and INS was measured by RIA (Diagnostic Systems Laboratories, Webster, TX, USA).
Measurement of complexed and fPSA
One vial of 200 μL per sample was provided blinded to Meso Scale Diagnostics (MSD) for cPSA and fPSA measurement using MSD's MULTI-ARRAY ® electrochemiluminescence technology in the S-PLEX™ format, which allows quantitation of previously unmeasurable levels of biomarkers with fg/mL sensitivity [27, 37] . The samples were thawed and centrifuged at 10,000 g for 10 min at 4 °C before being aliquoted into low retention 96-well round bottom plates for subsequent testing. Plates were immediately frozen on dry ice and stored at −80 °C until testing. cPSA and fPSA assays were calibrated to the WHO International Standard for PSA with 90% bound to ACT and 10% in the free form (National Institute for Biological Standards and Control (NIBSC), code 96/670, Hertfordshire, England) and the WHO International Standard for PSA free (NIBSC, code 96/668), respectively. Assay characteristics were determined before sample testing (see below).
For each assay eight-point calibration curves were included on each plate (Figure 1) , and the data were fitted with a weighted four-parameter logistic curve fit. Limit of detection (LOD) is a calculated concentration corresponding to the average signal 2.5 standard deviations above the background (zero calibrator). Lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ) are established for the plate lot by measuring multiple levels of calibrator near the expected LLOQ and ULOQ. LLOQ and ULOQ are, respectively, the lowest and highest concentration of calibrator tested which have a %CV of 20% or less, with recovered concentration within 70%-130%. The LOD was 5.7 and 140 fg/mL for cPSA and fPSA assays, respectively. Values of fPSA that were measured to be below the LOD (approximately 45% of the samples) were set to be equal to 70 fg/mL, or half the LOD. The LLOQ was 17 and 480 fg/mL for cPSA and fPSA assays, respectively. The ULOQ was 72,000 and 2,400,000 fg/mL for cPSA and fPSA assays, respectively. Precision was determined from testing of three internal quality control samples that span the detectable range and is expressed as the %CV from 16 specimen assay runs, with two operators over three testing days. % CVs were between 11% and 13% for cPSA and between 6% and 23% for fPSA. Serum, EDTA plasma and heparin plasma samples (seven to eight samples total) were spiked with calibrator at two or three concentrations. The noncomplexing form of PSA (Scripps Laboratories, San Diego, CA; #90024) that does not bind to ACT was used in spike recovery experiments for the fPSA assay. Average spike recoveries for the fPSA and cPSA assays were 88% and 90%, respectively. Serum, EDTA plasma and heparin plasma samples (seven to eight samples total) were diluted two, four and eightfold. Average dilution linearities for the fPSA and cPSA assays were 114% and 109%, respectively.
The samples and calibrator dilutions were assayed in duplicate, and all samples were measured for cPSA and fPSA. Measurement of cPSA was performed with a twofold dilution of the samples; fPSA measurement was performed on neat samples. Concentrations of biomarkers in each sample were calculated from the calibrator curves taking into account sample dilutions. The mean of two measurements was derived for each analyte in each sample and reported in fentogram per milliliter.
Statistical analysis
We first summarized the PCOS and control samples by several clinicopathological variables and hormonal measurements. When comparing clinical and hormonal variables among PCOS patients and controls, the Wilcoxon rank sum test was used to determine if there were significant differences in marker values. Marker correlations for PCOS samples and controls were examined using the Spearman correlation coefficients. We modeled the probability of a serum sample belonging to PCOS patients using logistic regression. Odds ratios (ORs), receiver operator characteristic (ROC) curves and area-underthe-ROC curve (AUC-ROC) were calculated for each covariate of interest.
We then fit several different multivariate logistic models and reported age/body mass index (BMI)/race-adjusted ORs for cPSA and fPSA and AUC-ROC performance. We also built the best predictive model among the set of all measured covariates using LASSO (least absolute shrinkage and selection operator) [38] , a variableselection method that aims to build simple models that have high predictive accuracy. Because we use the same data to both fit the model and evaluate its performance, bootstrap bias correction was used to adjust for over-optimism [39] .
Results
Characteristics of study subjects
The age range of the 45 PCOS subjects was 19 to 40 years (mean ± SD: 27.9 ± 5.26 years), and their BMI ranged from 19.5 to 55.6 kg/m 2 (37.6 ± 8.8 kg/m 2 ); 33 were White and 12 were Black or of other races. Control subjects ranged in age from 20 to 56 years (34.5 ± 8.6 years) with BMIs ranging from 25.3 to 58.7 kg/m 2 (32.74 ± 7.28 kg/m 2 ); 15 were White and 25 were Black or of other races. The differences of PCOS and controls in terms of age, BMI and race are significant, and these parameters were modeled as adjusting variables in the multivariate analysis (see below).
Relationship of cPSA and fPSA to clinical features and PCOS phenotypes
The distribution of cPSA and fPSA among women with PCOS by waist-to-hip ratio (WHR), dichotomized by the observed median value of 0.84, is depicted in Supplementary Figure 1 . Overall, there was no association between WHR and either cPSA or fPSA. Supplementary Figure 2 depicts the cPSA and fPSA values in three PCOS phenotypes: (a) those with hirsutism (i.e., mFG > 6) + hyperandrogenemia + oligo-ovulation (n = 20), (b) those with hirsutism + oligo-ovulation only (n = 8) and (c) those with hyperandrogenemia + oligo-ovulation only (n = 13). There is no difference in cPSA or fPSA between the three phenotypes of PCOS. Supplementary Figure 3 depicts the distributions of cPSA and fPSA in PCOS women with menstrual cycles <3 months (n = 13) and >3 months (n = 28). Again, there is no difference between these two groups of PCOS women for either cPSA or fPSA. Table 1 and Figure 2 present the distributions of all clinical and biochemical parameters between the control and the PCOS cohorts. All parameters, except GLU and INS, were significantly different between the two groups. Both cPSA and fPSA were, on average, about three times higher in PCOS vs. controls, and these differences were highly statistically significant. Figure 3 depicts the Spearman correlations between all continuous variables for both the PCOS and control groups. The strongest (and statistically significant) correlations of cPSA in the PCOS cohort were with fPSA, followed by FT and TT. Similarly, the strongest correlation of fPSA in PCOS was with cPSA, and then FT and TT. In control subjects, cPSA correlated strongly with fPSA, FT, A4 and the mFG score, whereas fPSA was not significantly correlated with any other hormones. Other significant and known correlations between various hormones and other analytes are depicted in Figure 3 .
Univariate and multivariate analysis
We developed univariate models for various clinicopathological variables and hormonal levels, calculating the ORs and constructing corresponding ROC curves. The OR for a patient with elevated cPSA having PCOS was 3.85 (95% confidence interval [CI]: 1.67, 10.0) and with elevated fPSA having PCOS was 4.74 (95% CI: 1.64, 4.1) ( Table 2 ). When OR was adjusted for age, categorical BMI and race, the OR increased to 5.67 (95% CI: 1.86, 22.0) and 7.04 (95% CI: 1.65, 40.4) for cPSA and fPSA, respectively, demonstrating that both cPSA and fPSA are associated with PCOS after adjustment for covariates. Table 1 . See nonstandard abbreviations for full list.
We then built multivariate models as follows: (a) including age, BMI, race and fPSA, which gave a bootstrap-corrected AUC-ROC of 0.88 (CI: 0.82-0.94); and (b) including age, BMI, race and cPSA, which gave a bootstrap-corrected AUC-ROC of 0.89 (CI: 0.83-0.95). These models along with their adjusted ORs demonstrate that cPSA and fPSA are both significantly associated with PCOS status, after adjusting for age, BMI and race, and have discriminatory capacity beyond these three adjusting variables, which have a combined AUC-ROC of 0.86 (95% CI: 0.79-0.93).
We used a method called LASSO [38] to build the most predictive multivariate model among the set of covariates shown in Table 2 . The model selected age, categorical BMI, race, FT, A4, DHEAS and SHBG and achieved an AUC of 0.97 (0.94, 0.98). A model that excluded FT and included fPSA gave identical performance. Finally, a model that replaced FT with A4 (i.e., included only age, categorical BMI, race, A4, DHEAS and SHBG) gave an AUC only slightly lower at 0.96 (0.95, 0.98).
Discussion
Previous studies have focused on the diagnostic value of PSA in women with PCOS and other hyperandrogenic states [12] [13] [14] [15] [16] [17] [18] . However, none of these studies had the ability to accurately quantify either total PSA or PSA subfractions in female serum because of their very low concentrations (<1 pg/mL) [25] . Recently developed fifth-generation assays can quantify PSA at extremely low levels, around 10-100 fg/mL [26] [27] [28] [29] [30] [31] 37] , sufficient to quantify both cPSA and fPSA in female serum. In the present study, for the first time, we report that the average concentration of complexed PSA in serum of normal women is approximately 942 fg/mL, whereas the concentration of fPSA is about 10 times lower, at around 70 fg/ mL. The ratio of cPSA/fPSA in males is similar, but their serum PSA is approximately 1000-fold higher. Previously, it has been documented that complexed PSA represents enzymatically active PSA bound to the proteinase inhibitor ACT, whereas fPSA represents a mixture of inactive forms of PSA such as pro PSA and internally clipped PSA [21, 22, 40] .
Our hypothesis that serum PSA in females may be a novel biomarker of hyperandrogenism is based on the fact that the PSA gene is upregulated by androgens, through the action of androgens on the androgen receptor [8] [9] [10] [11] . Previous studies have documented the presence of active androgen response elements within the PSA gene promoter and enhancer regions [41] [42] [43] . We hypothesized that in women with hyperandrogenism, whether clinically obvious or not, the PSA gene is unregulated, thus leading to increased PSA protein in female circulation. Our data support this hypothesis, demonstrating that both cPSA and fPSA are, on average, approximately threefold higher in women with PCOS than in control women. The involvement of androgens in the upregulation of the PSA gene in these women is further suggested by the significant correlations between both cPSA and fPSA with FT and TT levels in both PCOS and control women. Indeed, it seems plausible that the increased levels of both cPSA and fPSA in the female circulation of PCOS patients are driven by testosterone, as it has been shown in in vitro systems such as breast carcinoma cell lines [8] . In vivo, PSA is increased in both serum and urine after the administration of testosterone to young female-to-male transsexuals [19, 20] . Although we did not characterize the tissue source of PSA in this study, we have previously demonstrated that the major site of production of PSA in female tissues is the breast, and that PSA could be upregulated in this tissue by steroid hormones [11] .
We have previously observed very significant elevations in urinary PSA in women with hyperandrogenism [12] . However, we do not favor this fluid for diagnostic purposes because there is a significant chance of contamination of urine by seminal PSA during sexual intercourse. However, if urinary contamination by seminal fluid could be excluded, then, urinary PSA could be an even more sensitive marker of hyperandrogenism in women [12] .
ROC curve analysis of the various biochemical parameters measured in this study demonstrated that although all hormonal and PSA measurements are good biomarkers, the largest area under the curve was displayed by A4 and FT, followed by TT. We developed multivariate models that included age, BMI, race and fPSA or cPSA, and the AUC-ROC increased to 0.89. The most predictive multivariate model included age, categorical BMI, race, FT, A4, DHEAS and SHBG and achieved an AUC-ROC of 0.97. However, replacing FT for fPSA in this model yielded an identical predictive value.
We conclude that cPSA and fPSA can now be measured reliably in female serum with fifth-generation assays and that they are novel biomarkers for hyperandrogenism in women in PCOS. These new measures (cPSA and fPSA) may be useful, either alone or in combination with other existing markers, for better disease diagnosis in women with suspected PCOS.
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